In the Search for Biomarkers of Pulmonary Arterial Hypertension, Are Cytokines IL-2, IL-4, IL-6, IL-10, and IFN-Gamma the Right Indicators to Use?

Pulmonary arterial hypertension (PAH) is a complex disorder characterized by increased pressure in the pulmonary arteries, leading to right heart failure. While the exact mechanisms underlying PAH are not fully understood, cytokines have been implicated in the pathogenesis of the disease. Cytokines play a crucial role in regulating immune responses and inflammation. These small proteins also play a key role in shaping the immunophenotype, which refers to the specific characteristics and functional properties of immune cells, which can have a significant impact on the development of PAH. The aim of this study was to determine the immunophenotype and the concentration of selected cytokines, IL-2, IL-4, IL-6, IL-10, and IFN-gamma, in patients diagnosed with PAH (with particular emphasis on subtypes) in relation to healthy volunteers. Based on the obtained results, we can conclude that in patients with PAH, the functioning of the immune system is deregulated as a result of a decrease in the percentage of selected subpopulations of immune cells in peripheral blood and changes in the concentration of tested cytokines in relation to healthy volunteers. In addition, a detailed analysis showed that there are statistically significant differences between the PAH subtypes and the tested immunological parameters. This may indicate a significant role of the immune system in the pathogenesis of PAH.

[1]  E. Grywalska,et al.  CTLA-4 Expression Is a Promising Biomarker of Idiopathic Pulmonary Arterial Hypertension and Allows Differentiation of the Type of Pulmonary Hypertension , 2022, International journal of molecular sciences.

[2]  M. Humbert,et al.  2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. , 2022, European heart journal.

[3]  M. Kool,et al.  Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity , 2022, International journal of molecular sciences.

[4]  O. Kann,et al.  Priming of microglia by type II interferon is lasting and resistant to modulation by interleukin-10 in situ , 2022, Journal of Neuroimmunology.

[5]  E. Grywalska,et al.  Role of the Immune System Elements in Pulmonary Arterial Hypertension , 2021, Journal of clinical medicine.

[6]  M. Kool,et al.  Plasma markers in pulmonary hypertension subgroups correlate with patient survival , 2021, Respiratory Research.

[7]  J. Roliński,et al.  Overexpression of PD-1 on Peripheral Blood Lymphocytes in Patients with Idiopathic Pulmonary Arterial Hypertension and Its Association with High Viral Loads of Epstein-Barr Virus and Poor Clinical Parameters , 2020, Journal of clinical medicine.

[8]  B. Relja,et al.  Cytokines in Inflammatory Disease , 2019, International journal of molecular sciences.

[9]  S. Archer,et al.  Pulmonary arterial hypertension: pathogenesis and clinical management , 2018, British Medical Journal.

[10]  T. Thenappan,et al.  Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[11]  K. Tsuchiya,et al.  Novel CD200 homologues iSEC1 and iSEC2 are gastrointestinal secretory cell-specific ligands of inhibitory receptor CD200R , 2016, Scientific Reports.

[12]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[13]  K. Kamiński,et al.  Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. , 2015, Cytokine.

[14]  B. Lambrecht,et al.  T-helper 17 cell polarization in pulmonary arterial hypertension. , 2015, Chest.

[15]  C. Cheadle,et al.  Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension. , 2014, American journal of physiology. Lung cellular and molecular physiology.

[16]  R. Speich,et al.  Inflammatory cytokines in pulmonary hypertension , 2014, Respiratory Research.

[17]  Wei Chen,et al.  Decreased CD200R expression on monocyte-derived macrophages correlates with Th17/Treg imbalance and disease activity in rheumatoid arthritis patients , 2014, Inflammation Research.

[18]  M. Humbert,et al.  Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension , 2013, European Respiratory Journal.

[19]  S. Sarin,et al.  Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin , 2013, Journal of viral hepatitis.

[20]  Chris Cheadle,et al.  Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling , 2013, Respiratory Research.

[21]  Dong Woon Kim,et al.  Expression of CD200 in alternative activation of microglia following an excitotoxic lesion in the mouse hippocampus , 2012, Brain Research.

[22]  D. Knipe,et al.  CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-Inflammatory Signaling Functions of TLR2 , 2012, PloS one.

[23]  M. Toungouz,et al.  Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. , 2012, Immunology letters.

[24]  S. Halpern,et al.  Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. , 2011, Chest.

[25]  R. Trembath,et al.  Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension , 2010, Circulation.

[26]  S. Dhillon,et al.  Irreversible Pulmonary Hypertension Associated with the use of Interferon Alpha for Chronic Hepatitis C , 2010, Digestive Diseases and Sciences.

[27]  U. Rot,et al.  Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report , 2009, Multiple sclerosis.

[28]  L. Lue,et al.  Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: A potential mechanism leading to chronic inflammation , 2009, Experimental Neurology.

[29]  E. Mark,et al.  Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.

[30]  U. Ikeda,et al.  Interleukin-10 Expression Mediated by an Adeno-Associated Virus Vector Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[31]  N. Voelkel,et al.  Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. , 2007, American journal of respiratory and critical care medicine.

[32]  R. Johns,et al.  Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[33]  J. Phillips,et al.  Molecular Mechanisms of CD200 Inhibition of Mast Cell Activation , 2004, The Journal of Immunology.

[34]  M. Humbert,et al.  Treatment of pulmonary arterial hypertension. , 2004, The New England journal of medicine.

[35]  Joseph H. Phillips,et al.  Characterization of the CD200 Receptor Family in Mice and Humans and Their Interactions with CD200 1 , 2003, The Journal of Immunology.

[36]  U. Ikeda,et al.  Inflammatory cytokines and cardiovascular disease. , 2003, Current drug targets. Inflammation and allergy.

[37]  M. Minden,et al.  Vascular Events Associated with Alpha Interferon Therapy , 2003, Leukemia & lymphoma.

[38]  H. Saito,et al.  Induction of endothelin-1 synthesis by IL-2 and its modulation of rat intestinal epithelial cell growth. , 1998, The American journal of physiology.

[39]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[40]  A. Malik,et al.  IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes. , 1989, Journal of immunology.

[41]  R. Merchant,et al.  Cardiopulmonary effects of recombinant interleukin-2 infusion in sheep. , 1988, Journal of applied physiology.

[42]  R. Hendriks,et al.  A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. , 2018, Journal of autoimmunity.

[43]  A. Torbicki,et al.  Changing the strategy of balloon pulmonary angioplasty resulted in a reduced complication rate in patients with chronic thromboembolic pulmonary hypertension. A single-centre European experience. , 2017, Kardiologia polska.

[44]  Jun-Ming Zhang,et al.  Cytokines, Inflammation, and Pain , 2007, International anesthesiology clinics.